{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T05:42:15Z","timestamp":1786254135811,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10384-026-01359-8","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T07:51:02Z","timestamp":1775807462000},"page":"773-784","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Paired-eye comparison of photocoagulation versus intravitreal bevacizumab for retinopathy of prematurity: long-term visual, refractive, and ocular biometric outcomes at corrected ages 1, 5, and 9 years"],"prefix":"10.1007","volume":"70","author":[{"given":"Yoshimi","family":"Fukushima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Machi","family":"Takata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiteru","family":"Kawahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Chuman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhisa","family":"Naoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"1359_CR1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1046\/j.1442-9071.2000.00226.x","volume":"28","author":"HL Naug","year":"2000","unstructured":"Naug HL, Browning J, Gole GA, Gobe G. Vitreal macrophages express vascular endothelial growth factor in oxygen-induced retinopathy. Clin Exp Ophthalmol. 2000;28:48\u201352.","journal-title":"Clin Exp Ophthalmol"},{"key":"1359_CR2","first-page":"90","volume":"106","author":"JZ Nowak","year":"2004","unstructured":"Nowak JZ, Wiktorowska-Owczarek A. Neovascularization in ocular tissues: mechanisms and role of proangiogenic and antiangiogenic factors. Klin Oczna. 2004;106:90\u20137 ((in Polish)).","journal-title":"Klin Oczna"},{"key":"1359_CR3","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1097\/IAE.0b013e318177f934","volume":"28","author":"HA Mintz-Hittner","year":"2008","unstructured":"Mintz-Hittner HA, Kuffel RR Jr. Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina. 2008;28:831\u20138.","journal-title":"Retina"},{"key":"1359_CR4","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1097\/IAE.0b013e318159ec6b","volume":"28","author":"H Quiroz-Mercado","year":"2008","unstructured":"Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez-Rojas ML, Salazar-Teran N, Chan RVP. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina. 2008;28:S19-25.","journal-title":"Retina"},{"key":"1359_CR5","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1136\/bjo.2008.140657","volume":"92","author":"S Kusaka","year":"2008","unstructured":"Kusaka S, Shima C, Wada K, Arahori H, Shimojyo H, Sato T, et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol. 2008;92:1450\u20135.","journal-title":"Br J Ophthalmol"},{"key":"1359_CR6","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1089\/jop.2011.0060","volume":"27","author":"BC Harder","year":"2011","unstructured":"Harder BC, von Baltz S, Jonas JB, Schlichtenbrede FC. Intravitreal bevacizumab for retinopathy of prematurity. J Ocul Pharmacol Ther. 2011;27:623\u20137.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1359_CR7","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603\u201315.","journal-title":"N Engl J Med"},{"key":"1359_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102567","volume":"71","author":"N Marlow","year":"2024","unstructured":"Marlow N, Reynolds JD, Lepore D, Fielder AR, Stahl A, Hao H, et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): five-year outcomes of a randomised trial. EClinicalMedicine. 2024;71:102567.","journal-title":"EClinicalMedicine"},{"key":"1359_CR9","doi-asserted-by":"publisher","DOI":"10.1159\/000549717","author":"A Stahl","year":"2026","unstructured":"Stahl A, Nakanishi H, Lepore D, Wu WC, Azuma N, Jacas C, et al. Three-year outcomes of intravitreal aflibercept versus laser therapy for retinopathy of prematurity. Neonatology. 2026. https:\/\/doi.org\/10.1159\/000549717.","journal-title":"Neonatology"},{"key":"1359_CR10","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1038\/s41433-023-02559-z","volume":"37","author":"T Murakami","year":"2023","unstructured":"Murakami T, Okamoto F, Kinoshita T, Shinomiya K, Nishi T, Obata S, et al. Comparison of long-term treatment outcomes of laser and anti-VEGF therapy in retinopathy of prematurity: a multicentre study from J-CREST group. Eye (Lond). 2023;37:3589\u201395.","journal-title":"Eye (Lond)"},{"key":"1359_CR11","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early treatment for retinopathy of prematurity cooperative group","year":"2003","unstructured":"Early treatment for retinopathy of prematurity cooperative group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121:1684\u201394.","journal-title":"Arch Ophthalmol"},{"key":"1359_CR12","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transpl. 2013;48:452\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"1359_CR13","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/aos.12053","volume":"91","author":"CS Yang","year":"2013","unstructured":"Yang CS, Wang AG, Shih YF, Hsu WM. Long-term biometric optic components of diode laser-treated threshold retinopathy of prematurity at 9 years of age. Acta Ophthalmol. 2013;91:276\u201382.","journal-title":"Acta Ophthalmol"},{"key":"1359_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jaapos.2004.12.018","volume":"9","author":"E Garcia-Valenzuela","year":"2005","unstructured":"Garcia-Valenzuela E, Kaufman LM. High myopia associated with retinopathy of prematurity is primarily lenticular. J AAPOS. 2005;9:121\u20138.","journal-title":"J AAPOS"},{"key":"1359_CR15","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","volume":"132","author":"MM Geloneck","year":"2014","unstructured":"Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA, et al. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol. 2014;132:1327\u201333.","journal-title":"JAMA Ophthalmol."},{"key":"1359_CR16","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1001\/archopht.1985.01050060045020","volume":"103","author":"RA Gordon","year":"1985","unstructured":"Gordon RA, Donzis PB. Refractive development of the human eye. Arch Ophthalmol. 1985;103:785\u20139.","journal-title":"Arch Ophthalmol"},{"key":"1359_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-042384","volume":"11","author":"KQ Kong","year":"2021","unstructured":"Kong KQ, Ming WK, Mi XS. Refractive outcomes after intravitreal injection of antivascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity: a meta-analysis. BMJ Open. 2021;11:e042384.","journal-title":"BMJ Open"},{"key":"1359_CR18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ajo.2018.05.002","volume":"192","author":"YS Lee","year":"2018","unstructured":"Lee YS, See LC, Chang SH, Wang NK, Hwang YS, Lai CC, et al. Macular structures, optical components, and visual acuity in preschool children after intravitreal bevacizumab or laser treatment. Am J Ophthalmol. 2018;192:20\u201330.","journal-title":"Am J Ophthalmol"},{"key":"1359_CR19","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/bjophthalmol-2019-314610","volume":"104","author":"YC Chen","year":"2020","unstructured":"Chen YC, Chen SN. Foveal microvasculature, refractive errors, optical biometry and their correlations in school-aged children with retinopathy of prematurity after intravitreal antivascular endothelial growth factors or laser photocoagulation. Br J Ophthalmol. 2020;104:691\u20136.","journal-title":"Br J Ophthalmol"},{"key":"1359_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00417-018-4162-y","volume":"257","author":"C Yen-Chih","year":"2019","unstructured":"Yen-Chih C, Yan-Ting C, San-Ni C. Foveal microvascular anomalies on optical coherence tomography angiography and the correlation with foveal thickness and visual acuity in retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2019;257:23\u201330.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1359_CR21","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/eye.2014.94","volume":"28","author":"J Hanhart","year":"2014","unstructured":"Hanhart J, Tiosano L, Averbukh E, Banin E, Hemo I, Chowers I. Fellow eye effect of unilateral intravitreal bevacizumab injection in eyes with diabetic macular edema. Eye (Lond). 2014;28:646\u201353.","journal-title":"Eye (Lond)"},{"key":"1359_CR22","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2147\/CIA.S93820","volume":"11","author":"K Michalska-Malecka","year":"2016","unstructured":"Michalska-Malecka K, Kabiesz A, Kimsa MW, Strzalka-Mrozik B, Forminska-Kapuscik M, Nita M, et al. Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration. Clin Interv Aging. 2016;11:357\u201365.","journal-title":"Clin Interv Aging"},{"key":"1359_CR23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jaapos.2011.11.002","volume":"16","author":"RL Avery","year":"2012","unstructured":"Avery RL. Bevacizumab (Avastin) for retinopathy of prematurity: wrong dose, wrong drug, or both? J AAPOS. 2012;16:2\u20134.","journal-title":"J AAPOS"},{"key":"1359_CR24","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s10384-025-01199-y","volume":"69","author":"Y Nakagawa","year":"2025","unstructured":"Nakagawa Y, Murayama Y, Suzuki Y, Uchiyama A, Suzuki T. Therapeutic outcomes of ranibizumab for zone II stage 2 retinopathy of prematurity with plus disease. Jpn J Ophthalmol. 2025;69:543\u20138.","journal-title":"Jpn J Ophthalmol"},{"issue":"3","key":"1359_CR25","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jaapos.2021.02.004","volume":"25","author":"K Taylor","year":"2021","unstructured":"Taylor K, Ghergherehchi L, Rao P, Harper CA 3rd, Chang E. Very late-onset reactivation of retinopathy of prematurity post anti-VEGF bevacizumab treatment for type 1 ROP: a case report. J AAPOS. 2021;25(3):180\u20134.","journal-title":"J AAPOS"},{"key":"1359_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fopht.2023.1270591","volume":"3","author":"A Ajjarapu","year":"2023","unstructured":"Ajjarapu A, Dumitrescu A. Delayed anterior segment complications after the treatment of retinopathy of prematurity with laser photocoagulation. Front Ophthalmol. 2023;3:1270591.","journal-title":"Front Ophthalmol"}],"updated-by":[{"DOI":"10.1007\/s10384-026-01405-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000}}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-026-01359-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-026-01359-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-026-01359-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T05:31:30Z","timestamp":1786253490000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-026-01359-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1359"],"URL":"https:\/\/doi.org\/10.1007\/s10384-026-01359-8","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"23 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10384-026-01405-5","URL":"https:\/\/doi.org\/10.1007\/s10384-026-01405-5","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Fukushima, None; M. Takata, None; A. Kawahara, None; H. Chuman, None; N. Naoi, None; Y. Ikeda, None.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}